fluasterone (ST-002) / SteroTherap - LARVOL DELTA

Sterotherapeutics, Announces Initiation of a Phase 2 Clinical Trial for Patients with Cushing's Syndrome (PRNewswire) - "Sterotherapeutics...is announcing the launch of a Phase 2 clinical trial for ST-002, a novel drug candidate for patients with Cushing's Syndrome, a rare endocrine disorder with very limited available therapeutic options. An Investigators Meeting to start this study is scheduled for Monday, 24 February 2025, in Athens, Greece, when clinical investigators, research coordinators, and stakeholders will discuss trial objectives, protocol details, and best practices for successful execution of this highly anticipated clinical trial."

New P2 trial • Cushing’s Disease